|Master Investor Magazine
Never miss an issue of Master Investor Magazine – sign-up now for free!
The share price of AIM-listed data analytics business Diaceutics (LON:DXRX) improved by 11.72% to 113.95p (as of 14:30 GMT) after revenues for the year ended 31st December climbed by 28%. Adjusted EBITDA was also ahead of expectations as it rose by 40% over the period.
CEO Peter Keeling commented: “We are pleased to have delivered on both our operational and financial commitments, exceeding full year guidance, while continuing to invest in the long-term future of the Group. 2019 was a key year in expanding our global footprint and deepening our service relationships with key clients and their therapy brands. These results provide a solid base for 2020 and the launch of our Nexus platform later in 2020“.
The Master Investor Show 2020 tickets are now available. Join us at the Business Design Centre on Saturday 28 March 2020.
Book your FREE tickets today using code: MIBLOG